Who We Are

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.

Our Pipeline

Our lead product, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01’s novel mechanism of action is designed to reestablish tear film homeostasis by activating natural tear film production.

Latest News

8/5/2020

Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights

7/31/2020

Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020